GSK press releases
Follow
GSK completes acquisition of efimosfermin, a potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
GSK plc today announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals
